Browse the evidence

Diet and exercise are not effective as sole management of severe obesity.

Clinicians should consider additional interventions beyond diet and exercise for severe obesity.

Allodynia was observed in 4 patients associated with dose escalation of semaglutide.

Clinicians should be aware of the potential for allodynia in patients taking semaglutide.

Therapy was stopped in 2 patients, both of whom had resolution of symptoms.

Stopping semaglutide may resolve allodynia symptoms in affected patients.

Two patients opted to continue semaglutide despite the adverse effect, with one experiencing resolution after 4 months.

Some patients may choose to continue semaglutide, and symptom resolution can occur over time.

Retatrutide raises cardiovascular safety concerns due to dose-dependent increases in heart rate and incidents of mild to moderate cardiac arrhythmias.

Clinicians should monitor cardiovascular health in patients using retatrutide.

Redemption was higher for females, Asian participants, and those reporting Spanish as their preferred language compared to their counterparts.

Demographic factors such as gender, ethnicity, and language preference may influence redemption rates in produce prescription programs.

BI 1820237 treatment was associated with transient nausea and vomiting at higher doses.

Practitioners should monitor for gastrointestinal side effects when prescribing BI 1820237.

Drug-related adverse events (AEs) were reported by 39.0% of participants in parts 1 + 2 and 30.6% in part 3.

Practitioners should be aware of the incidence of AEs when considering BI 1820237 for treatment.

Newer antiretroviral agents have been consistently associated with excessive weight gain.

Clinicians should consider the weight gain potential of newer ART agents when prescribing.

Current anti-obesity drugs have limitations regarding efficacy, side effects, weight regain, and high costs.

Awareness of these limitations can guide practitioners in seeking innovative treatment options.

The review focuses on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the context of anti-obesity drug discovery.

Practitioners should consider the role of GLP-1 RAs in developing new anti-obesity therapies.

No significant further benefits of ingesting multi-ingredient supplements (MTN) compared to calorie equivalent comparator (COMP) supplements were identified for fat-free mass (FFM), upper-body strength, lower-body strength, and functional capacity.

Practitioners should consider that multi-ingredient supplements may not provide additional benefits over calorie equivalent supplements for body composition and performance in this population.

Obesity is a debilitating disease that requires refined, concept-driven therapeutic approaches.

Health professionals should adopt refined therapeutic approaches to address obesity.

The 'Behavioral Balance Model' integrates biological, psychological, social, economic, and environmental aspects of obesity.

Practitioners should consider a multifaceted approach to understanding and treating obesity.

Further studies are needed to investigate the safety and efficacy of glucagon and GLP-1 receptor co-agonists.

Practitioners should be aware that while glucagon and GLP-1 co-agonists show promise, more research is needed before widespread clinical application.

Adverse events from SGLT-2 inhibitors and GLP-1RAs are primarily mild to moderate and tend to subside with treatment adjustment.

Practitioners should monitor for mild to moderate gastrointestinal side effects when prescribing these medications.

Future research is needed to determine the ideal SGLT-2 inhibitor or GLP-1RA for weight loss management and the efficacy of combination therapies.

Practitioners should stay informed about ongoing research for optimal weight loss strategies using these medications.

Caution is advised when initiating GLP-1 agonist therapy in HIV patients taking protease inhibitors.

Healthcare providers should monitor HIV patients on protease inhibitors closely when starting GLP-1 agonists.

Amylin promotes satiation and recruits multiple central nervous system pathways to regulate food intake.

Understanding amylin's role can help in developing obesity treatments.

Cagrilintide, a stable amylin analogue, is under clinical development for obesity treatment.

Cagrilintide may offer a new approach to obesity management.

Nonshivering thermogenesis (NST) has potential for activating energy balance processes without significant side effects.

Practitioners may consider NST as a viable strategy for enhancing energy balance in obesity management.

Combination therapy of metabolic boosters and established anti-obesity compounds is a promising future approach.

Practitioners should explore combination therapies as a potential strategy for obesity treatment.

There was no significant relative change in disability benefit receipt for the ILI group compared to controls.

Intensive lifestyle interventions may not affect disability benefit receipt despite improving employment.

Whey protein supplementation did not differentially influence performance, cardiorespiratory fitness, upper and lower body strength, immune or hormonal adaptations following 6 weeks of concurrent training.

Practitioners should note that whey protein supplementation may not provide additional benefits during concurrent training.